261 related articles for article (PubMed ID: 18697784)
1. Could tumour necrosis factor blockers inhibit the progression of future structural damage in ankylosing spondylitis?
Gaspersic N; Sersa I; Jevtic V; Tomsic M; Praprotnik S
Ann Rheum Dis; 2008 Sep; 67(9):1354. PubMed ID: 18697784
[No Abstract] [Full Text] [Related]
2. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
Sieper J; Rudwaleit M
Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
[TBL] [Abstract][Full Text] [Related]
3. Uveitis and tumour necrosis factor blockade in ankylosing spondylitis.
Coates LC; McGonagle DG; Bennett AN; Emery P; Marzo-Ortega H
Ann Rheum Dis; 2008 May; 67(5):729-30. PubMed ID: 18408116
[No Abstract] [Full Text] [Related]
4. BSR guidelines for prescribing TNF-alpha blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology.
Keat A; Barkham N; Bhalla A; Gaffney K; Marzo-Ortega H; Paul S; Rogers F; Somerville M; Sturrock R; Wordsworth P;
Rheumatology (Oxford); 2005 Jul; 44(7):939-47. PubMed ID: 15901904
[No Abstract] [Full Text] [Related]
5. Erythema multiforme with tumour necrosis factor inhibitors: a class effect?
Kain T; MacGregor D; Buchanan RR; de Jager JP; Schachna L
Ann Rheum Dis; 2008 Jun; 67(6):899-900. PubMed ID: 18474663
[No Abstract] [Full Text] [Related]
6. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation.
de Vries MK; Wolbink GJ; Stapel SO; de Groot ER; Dijkmans BA; Aarden LA; van der Horst-Bruinsma IE
Ann Rheum Dis; 2007 Jan; 66(1):133-4. PubMed ID: 17178760
[No Abstract] [Full Text] [Related]
7. Do TNF-blockers reduce or induce uveitis?
Cobo-Ibáñez T; del Carmen Ordóñez M; Muñoz-Fernández S; Madero-Prado R; Martín-Mola E
Rheumatology (Oxford); 2008 May; 47(5):731-2. PubMed ID: 18346974
[No Abstract] [Full Text] [Related]
8. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes.
Sieper J; Appel H; Braun J; Rudwaleit M
Arthritis Rheum; 2008 Mar; 58(3):649-56. PubMed ID: 18311819
[No Abstract] [Full Text] [Related]
9. Therapeutic controversies: tumor necrosis factor α inhibitors in ankylosing spondylitis.
Song IH; Maksymowych WP
Rheum Dis Clin North Am; 2012 Aug; 38(3):613-33. PubMed ID: 23083759
[TBL] [Abstract][Full Text] [Related]
10. Antitumour necrosis factor-α therapy modulates angiopoietin-2 serum levels in non-diabetic ankylosing spondylitis patients.
Genre F; Miranda-Filloy JA; López-Mejias R; Carnero-López B; Ochoa R; Rueda J; González-Juanatey C; Blanco R; Llorca J; González-Gay MA
Ann Rheum Dis; 2013 Jul; 72(7):1265-7. PubMed ID: 23482472
[No Abstract] [Full Text] [Related]
11. Anti-tumour necrosis factor therapy for ankylosing spondylitis--unresolved issues.
Jois RN; Gaffney K; Keat A
Rheumatology (Oxford); 2007 Jun; 46(6):899-901. PubMed ID: 17308313
[No Abstract] [Full Text] [Related]
12. High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers.
Hermann J; Müller T; Yazdani-Biuki B; Aringer M; Herold M; Ebner W; Ofner P; Graninger W
Ann Rheum Dis; 2007 Apr; 66(4):561-2. PubMed ID: 17360786
[No Abstract] [Full Text] [Related]
13. Evidence in support of the validity of the TNF brake hypothesis.
Maksymowych WP
Ann Rheum Dis; 2013 Dec; 72(12):e31. PubMed ID: 23989987
[No Abstract] [Full Text] [Related]
14. Infliximab-induced palmoplantar psoriasis in a patient with ankylosing spondylitis.
Capkin E; Karkucak M; Yayli S; Aydin Çapkin A; Tosun M
J Clin Rheumatol; 2011 Aug; 17(5):293-4. PubMed ID: 21808187
[No Abstract] [Full Text] [Related]
15. Fibromyalgia in between: where do the musculoskeletal physicians and psychiatrists stand?
Algül A; Basoglu C; Kiralp MZ; Ozçakar L
Acta Reumatol Port; 2008; 33(4):477-8. PubMed ID: 19107094
[No Abstract] [Full Text] [Related]
16. Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker?
Haibel H; Sieper J
Curr Opin Rheumatol; 2010 Jul; 22(4):388-92. PubMed ID: 20473176
[TBL] [Abstract][Full Text] [Related]
17. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents.
Montagna GL; Malesci D; Buono R; Valentini G
Ann Rheum Dis; 2005 Nov; 64(11):1667. PubMed ID: 16227427
[No Abstract] [Full Text] [Related]
18. Anti-tumor necrosis factor therapies reduce serum macrophage inflammatory protein-1alpha in ankylosing spondylitis.
Akbulut H; Koca SS; Ozgen M; Isik A
J Rheumatol; 2010 May; 37(5):1073-4. PubMed ID: 20439531
[No Abstract] [Full Text] [Related]
19. Anti-tumour necrosis factor therapy in ankylosing spondylitis. A need for guidelines.
Kassimos DG; Garyfallos A; Delamere J; Whallett A; Kitas GD
Rheumatology (Oxford); 2003 Mar; 42(3):490. PubMed ID: 12626807
[No Abstract] [Full Text] [Related]
20. Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.
Genre F; López-Mejías R; Miranda-Filloy JA; Ubilla B; Carnero-López B; Gómez-Acebo I; Blanco R; Ochoa R; Rueda-Gotor J; Pina T; González-Juanatey C; Llorca J; González-Gay MA
Ann Rheum Dis; 2014 May; 73(5):941-3. PubMed ID: 24323393
[No Abstract] [Full Text] [Related]
[Next] [New Search]
